The US Food and Drug Administration has finalized new guidance clarifying how sponsors and requestors can formally dispute scientific or medical decisions related to over-the-counter (OTC) drug final orders. The guidance brings greater structure and predictability to the formal dispute resolution (FDR) and administrative hearing processes established under Section 505G of the Federal Food, Drug, and Cosmetic Act.
This update is particularly relevant for companies navigating the modernized OTC monograph system, where FDA now issues proposed and final orders that can add, remove, or modify conditions under which OTC drugs are considered generally recognized as safe and effective.
Background on the OTC Order Dispute Framework
Under Section 505G, FDA has authority to initiate or respond to requests for orders affecting OTC drug monographs. When a final order is issued, eligible requestors or sponsors that participated throughout the order process may seek to challenge FDA’s decision through either a formal dispute resolution process or an administrative hearing.
The finalized guidance implements provisions introduced through the CARES Act and negotiated as part of the Over-the-Counter Monograph User Fee Act. Its goal is to ensure sponsors have a defined opportunity to appeal scientific or medical determinations while preventing duplicative or inefficient review processes.
Key Clarifications in the Final Guidance
One of the most significant updates is FDA’s clarification of the limits of the FDR process. The agency emphasized that dispute resolution requests under this framework are confined to specific aspects of Section 505G and may not be used simultaneously to pursue multiple regulatory or legal avenues for the same issue.
The guidance also formalizes FDA’s approach to consolidated proceedings. When multiple FDR requests or hearing requests are submitted for the same final order, FDA may consolidate them into a single proceeding. This approach is intended to improve efficiency and consistency in decision-making.
New Timelines and Preliminary Review Process
FDA also introduced clearer timelines and expectations for how FDR requests will be handled. Within 30 calendar days of receiving a request, FDA will conduct a preliminary review to determine whether the request was submitted within the statutory timeframe and whether the requester is eligible.
Following this review, FDA will notify the requester whether the appeal has been accepted or rejected. If accepted, FDA will identify the deciding official, provide a target date for FDA’s response, and outline any next steps, including meetings if applicable. When consolidation is appropriate, FDA will notify all affected parties.
These procedural details provide sponsors with greater transparency and predictability when considering whether to pursue a dispute.
What This Means for OTC Sponsors
The final guidance reinforces that while FDA is committed to due process, the dispute framework is narrow, structured, and time-bound. Sponsors must carefully assess eligibility, scope, and strategic implications before pursuing an FDR or administrative hearing.
Early planning, strong scientific justification, and clear alignment with Section 505G requirements are essential to using this pathway effectively.
How EMMA International Supports OTC Regulatory Strategy
At EMMA International, we support OTC sponsors navigating the modern monograph system, including order strategy, dispute readiness, and regulatory engagement planning. Our teams help clients evaluate whether formal dispute resolution is appropriate, prepare scientifically sound submissions, and manage interactions with FDA efficiently and strategically.
For more information on how EMMA International can assist, visit www.emmainternational.com or contact us at (248) 987-4497 or info@emmainternational.com.
Reference:
U.S. Food and Drug Administration. Final guidance on formal dispute resolution and administrative hearings for OTC drug final orders. December 2025.
U.S. Food and Drug Administration. Section 505G of the Federal Food, Drug, and Cosmetic Act and OTC monograph reform overview. FDA.
Regulatory Affairs Professionals Society. FDA clarifies process for disputing OTC orders in final guidance. January 5, 2026.
